T. Rowe Price Investment Management, Inc. Akero Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,767,243 shares of AKRO stock, worth $48.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,767,243
Previous 1,102,049
60.36%
Holding current value
$48.9 Million
Previous $27.8 Million
48.93%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
168Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$190 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$154 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$150 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$145 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$141 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.28B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...